Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
When stomach cancer becomes advanced, choosing where to receive treatment becomes more complicated.
You may already have received chemotherapy or surgery. Perhaps immunotherapy has been discussed, or your current treatment has stopped controlling the disease. At that point, families often begin searching for the best medical centers specializing in advanced stomach cancer treatment.
The hospital name matters, but it should not be the only consideration. Advanced gastric cancer is increasingly treated according to the molecular characteristics of the tumor. A center with expertise in HER2-positive disease may be particularly relevant to one patient, while another may need a team experienced with CLDN18.2-targeted treatment or an appropriate clinical trial.
Current National Cancer Institute guidance reflects this increasingly personalized approach. Treatment for stage IV, inoperable and recurrent gastric cancer can include chemotherapy, immunotherapy, targeted therapies and palliative local treatments, depending on the individual case and biomarkers.
Key Takeaways |
|
What Should I Look For In A Medical Center For Advanced Stomach Cancer?
A strong gastric-cancer center should offer more than access to chemotherapy.
Ideally, the hospital should have gastrointestinal medical oncologists, gastric-cancer surgeons, radiation oncologists, gastrointestinal pathologists, molecular diagnostics and a clinical-trial program working together.
For advanced disease, molecular testing is particularly important.
The NCI recommends consideration of testing for HER2, mismatch-repair deficiency or microsatellite instability and PD-L1 in metastatic gastric adenocarcinoma. CLDN18.2 has also become clinically important because therapies are now available for selected CLDN18.2-positive tumors.
A specialist center should therefore be able to answer two different questions:
What established treatment is appropriate now?
And:
If standard treatments stop working, what should we consider next?
The second question is where access to research programs and clinical trials can become especially important.
Which Types Of Medical Centers Specialize In Advanced Gastric Cancer?
For most patients, the strongest starting point is a large academic cancer center or university-affiliated hospital with a dedicated gastrointestinal oncology program
In the United States and other countries, these centers may provide multidisciplinary review, molecular tumor boards and access to trials of newer drugs.
For patients exploring China, major academic oncology institutions are also involved in gastric-cancer research.
For example, Peking University Cancer Hospital has been involved in the development and study of CLDN18.2-targeted CAR-T therapies. Researchers affiliated with its gastrointestinal oncology and early drug-development programs have published and presented clinical research involving cellular therapy for advanced gastrointestinal cancers.
Fudan University Shanghai Cancer Center is another major Chinese academic cancer center participating in advanced gastric-cancer research. Its medical oncology investigators were among the researchers involved in a 2026 phase II study evaluating a CLDN18.2-targeted antibody-drug conjugate combination for advanced gastric or gastroesophageal-junction adenocarcinoma.
Other Chinese academic centers are participating in multicenter gastric-cancer studies involving targeted therapy, immunotherapy and precision medicine.
This does not establish a universal ranking of hospitals. The more useful question is whether a particular center has expertise and an active program that matches your tumor and treatment history.
Why Is Biomarker Testing So Important When Choosing A Treatment Center?
Advanced stomach cancer is no longer treated as one biological disease.
A 2026 Chinese expert consensus describes precision treatment as increasingly driven by biomarkers including HER2, MSI-H, PD-L1 and CLDN18.2.
HER2-positive disease can lead to HER2-directed treatment.
PD-L1 expression can affect the role of particular immunotherapy strategies.
MSI-high or mismatch-repair-deficient disease can be especially important when evaluating immune-based therapy.
CLDN18.2 has created another treatment pathway. The NCI now includes the CLDN18.2-targeted antibody zolbetuximab plus chemotherapy among treatment options for appropriately selected HER2-negative metastatic gastric or gastroesophageal adenocarcinoma.
For patients whose cancer has already progressed through multiple therapies, CLDN18.2 may also have implications for cellular therapy in China.
This is why sending your records to a specialist center without including existing molecular results can lead to an incomplete review.
Why Are Chinese Cancer Centers Attracting Attention For Advanced Stomach Cancer?
China has a large gastric-cancer patient population and an active clinical-research environment.
One important example is satricabtagene autoleucel (satri-cel/CT041), a CAR-T therapy targeting CLDN18.2.
In a phase 1 study involving 98 patients with CLDN18.2-positive advanced gastrointestinal cancers, the overall response rate was 38.8% and the disease-control rate was 91.8%. Median progression-free survival was 4.4 months and median overall survival was 8.8 months. Cytokine release syndrome occurred in 96.9% of patients but was grade 1–2 in that study.
Researchers subsequently conducted a randomized phase 2 trial in China involving patients with CLDN18.2-positive advanced gastric or gastroesophageal-junction cancer whose disease was refractory to at least two previous treatment lines.
In June 2026, China's National Medical Products Administration approved satri-cel for CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastroesophageal-junction adenocarcinoma after progression following at least two previous lines of treatment.
That is an important development, but it does not mean CAR-T is suitable for every patient with advanced stomach cancer.
Patients must meet specific criteria, and CAR-T requires specialist evaluation, cell collection, manufacturing, preparatory treatment and close monitoring.
Are Chinese Hospitals Still Running Clinical Trials For Advanced Gastric Cancer?
Yes. Research extends well beyond one CAR-T product.
In 2026, investigators from Chinese centers reported early clinical research involving a dual-targeting CAR-T approach against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers.
Another phase I program reported data on IMC002, an anti-CLDN18.2 CAR-T therapy, with investigators noting that a phase III randomized study had been initiated.
Research is also taking place outside cellular therapy. A phase II study involving Chinese institutions is evaluating the CLDN18.2-targeted antibody-drug conjugate tecotabart vedotin with immunotherapy, with or without chemotherapy, in advanced gastric or gastroesophageal-junction adenocarcinoma.
Another multicenter phase II study in China is evaluating SKB315 plus a PD-1 inhibitor, with or without capecitabine, in CLDN18.2-positive unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma.
These studies help explain why China may be worth investigating for selected patients who are looking beyond standard treatment.
However, a clinical trial is not the same as an approved therapy, and being interested in a trial does not mean a patient will qualify.
How Should I Choose Between Medical Centers?
Start with your cancer rather than the hospital's reputation.
A useful hospital comparison should consider whether the center has experience with your exact diagnosis, which biomarkers it routinely evaluates, what treatments you have already received and whether the center has a relevant clinical program.
For example, someone with newly diagnosed HER2-positive metastatic gastric cancer has different needs from a patient with CLDN18.2-positive disease that has progressed after three previous treatment lines.
Before approaching a center, prepare your pathology report, imaging, treatment history, surgical records and molecular testing.
Then ask the hospital:
What treatment would you recommend based on my current records?
Do I need additional biomarker testing?
Is the proposed treatment approved or investigational?
Do you have a clinical trial relevant to my tumor profile?
What evidence supports the treatment?
What are the main risks?
These questions are more useful than simply asking whether a hospital is “the best.”
Should I Travel Internationally For Advanced Stomach Cancer Treatment?
Sometimes—but ideally not before your records have been reviewed.
International treatment makes the most sense when there is a specific reason to travel: a specialist opinion, treatment, technology or clinical trial that may be relevant and is difficult to access at home.
Before arranging flights, ask the overseas hospital to review your medical information.
For someone considering China, that means sending pathology, scans, previous treatment history and biomarker results to an appropriate gastric-cancer team.
If the hospital identifies a potentially relevant treatment or trial, you can then investigate eligibility, expected length of stay, costs, treatment risks and follow-up requirements.
This approach avoids travelling internationally simply to discover that you are not eligible for the treatment you were hoping to receive.
How ChinaCureLink Can Help Patients With Advanced Stomach Cancer
ChinaCureLink helps international patients explore advanced cancer treatment at major hospitals in China.
For advanced gastric cancer, the process can begin remotely with your medical records. Pathology, imaging, previous treatment history and biomarker results can be organized for specialist evaluation.
Based on the individual case, ChinaCureLink can help identify Chinese hospitals with relevant gastrointestinal oncology expertise and coordinate communication with the medical team.
For selected patients, this may include evaluating access to targeted therapy, immunotherapy, CAR-T or clinical trials.
If a hospital believes there is a relevant treatment pathway, ChinaCureLink can then assist with hospital coordination, translation and international patient logistics.
The purpose is not to label one Chinese hospital as universally “best.” It is to help identify which center has the expertise and treatment program most relevant to the individual patient's cancer.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
What Type Of Hospital Is Best For Advanced Stomach Cancer?
Look for a major cancer center with a dedicated gastrointestinal oncology program, multidisciplinary review, molecular testing and clinical-trial capabilities. The appropriate hospital depends on your tumor biology and previous treatment.
Which Biomarkers Are Important In Advanced Gastric Cancer?
HER2, PD-L1 and MSI/MMR are important biomarkers in advanced gastric cancer. CLDN18.2 is also increasingly relevant because it can affect eligibility for targeted therapies and, in specific circumstances, CAR-T treatment.
Is CAR-T Available For Advanced Stomach Cancer?
China approved satri-cel in June 2026 for a defined group of patients with CLDN18.2-positive, HER2-negative unresectable advanced gastric or GEJ adenocarcinoma after progression following at least two prior treatment lines. It is not appropriate for every patient.
Are There Clinical Trials For Advanced Stomach Cancer In China?
Yes. Chinese institutions are studying CAR-T, antibody-drug conjugates, immunotherapy combinations and other biomarker-driven approaches for advanced gastric and GEJ cancers.
Should I Get A Second Opinion Before Travelling To China?
A remote specialist review is a sensible first step. It allows the Chinese medical team to examine your diagnosis, previous treatments, imaging and biomarkers before determining whether a particular treatment or clinical trial may be relevant.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
National Cancer Institute. Gastric Cancer Treatment (PDQ®). NCI Gastric Cancer Treatment
Qi C, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nature Medicine, 2024.PubMed — Satri-cel Phase 1 Results
Qi C, et al. Claudin-18 isoform 2-specific CAR T-cell therapy versus physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer. The Lancet, 2025.PubMed — Satri-cel Phase 2 Trial
Chinese consensus on first-line precision therapy for advanced gastric cancer. 2026. Chinese Precision-Therapy Consensus
ClinicalTrials.gov. SKB315 Combination Therapy in Advanced or Metastatic Gastric/GEJ Adenocarcinoma. ClinicalTrials.gov Study Record
Zhang P, et al. Dual-targeting CAR-T cells against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers. Journal of Clinical Oncology, 2026.ASCO 2026 Study Abstract